METAGENOMI INC (MGX) Stock Price, Quote, News and Overview
NASDAQ:MGX - Nasdaq - US59102M1045 - Common Stock - Currency: USD
MGX Quote, Performance and Key Statistics
1.74
-0.01 (-0.57%)
The current stock price of MGX is 1.74 USD. In the past month the price increased by 12.99%. In the past year, price decreased by -76.89%.
MGX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About MGX
Company Profile
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. The company is headquartered in Emeryville, California and currently employs 202 full-time employees. The company went IPO on 2024-02-09. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The firm uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
Company Info
METAGENOMI INC
5959 Horton St, Floor 7
Emeryville CALIFORNIA US
Employees: 202
Company Website: https://metagenomi.co/
Phone: 15108714880
METAGENOMI INC / MGX FAQ
What is the stock price of METAGENOMI INC today?
The current stock price of MGX is 1.74 USD. The price decreased by -0.57% in the last trading session.
What is the ticker symbol for METAGENOMI INC stock?
The exchange symbol of METAGENOMI INC is MGX and it is listed on the Nasdaq exchange.
On which exchange is MGX stock listed?
MGX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for METAGENOMI INC stock?
11 analysts have analysed MGX and the average price target is 15.91 USD. This implies a price increase of 814.48% is expected in the next year compared to the current price of 1.74. Check the METAGENOMI INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is METAGENOMI INC worth?
METAGENOMI INC (MGX) has a market capitalization of 65.04M USD. This makes MGX a Micro Cap stock.
How many employees does METAGENOMI INC have?
METAGENOMI INC (MGX) currently has 202 employees.
What are the support and resistance levels for METAGENOMI INC (MGX) stock?
METAGENOMI INC (MGX) has a resistance level at 1.78. Check the full technical report for a detailed analysis of MGX support and resistance levels.
Is METAGENOMI INC (MGX) expected to grow?
The Revenue of METAGENOMI INC (MGX) is expected to decline by -38.41% in the next year. Check the estimates tab for more information on the MGX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy METAGENOMI INC (MGX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MGX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MGX, evaluating the profitability, health, valuation and growth aspects
- METAGENOMI INC (MGX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- METAGENOMI INC (MGX) Sales and EPS estimates to see what analysts future expectations are.
- METAGENOMI INC (MGX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- METAGENOMI INC (MGX) Insider and Institutional Ownership to learn about the owners and their transactions.
- METAGENOMI INC (MGX) Stock Chart to make your own analysis
- METAGENOMI INC (MGX) Latest news and press-releases to stay up to date.
Does METAGENOMI INC (MGX) stock pay dividends?
MGX does not pay a dividend.
When does METAGENOMI INC (MGX) report earnings?
METAGENOMI INC (MGX) will report earnings on 2025-05-20, after the market close.
What is the Price/Earnings (PE) ratio of METAGENOMI INC (MGX)?
METAGENOMI INC (MGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.62).
What is the Short Interest ratio of METAGENOMI INC (MGX) stock?
The outstanding short interest for METAGENOMI INC (MGX) is 9.98% of its float. Check the ownership tab for more information on the MGX short interest.
MGX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MGX. When comparing the yearly performance of all stocks, MGX is a bad performer in the overall market: 95.54% of all stocks are doing better.
MGX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MGX. While MGX has a great health rating, there are worries on its profitability.
MGX Financial Highlights
Over the last trailing twelve months MGX reported a non-GAAP Earnings per Share(EPS) of -2.62. The EPS decreased by -29.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.05% | ||
| ROE | -33.24% | ||
| Debt/Equity | 0 |
MGX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to MGX. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 7.06% and a revenue growth -38.41% for MGX